The reiteration of an Outperform rating and a maintained price target of $9 by a reputable analyst like David Nierengarten from Wedbush is likely to instill confidence among investors and could positively influence TScan Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.